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Background: Intestinal monocytes/macrophages sustain the intestinal immune homeostasis and might be an
attractive therapeutic target for the management of inflammatory bowel disease (IBD). Granulocyte macrophage
colony-stimulating factor (GM-CSF) exerts beneficial effects on intestinal inflammation and promotes signal
transducer and activator of transcription 3 (STAT3)-mediated expansion of myeloid-derived suppressor cells
(MDSCs). However, the full action mechanism of GM-CSF, and especially whether monocytes mediate its
therapeutic effects in vivo, had not been previously elucidated.
Conclusions: This review article summarizes recent developments in the immunology of mucosal diseases and
describes new aspects of the role of myeloid regulatory cells in IBD and the function of GM-CSF in maintaining
the intestinal immune homeostasis in Crohn’s disease (CD). This review article highlights the exploration of stimulating
in addition to suppressive therapies for patients with IBD and underpins that myeloid regulatory cells might become a
promising novel cell-based therapeutic option.
Introduction
Crohn’s disease (CD) is a chronic relapsing disease and
is a manifestation of a dysregulated immune response
against the microorganisms of the intestinal flora in gen-
etically susceptible individuals [1]. Various components
of the mucosal immune system are implicated in the
pathogenesis of inflammatory bowel diseases (IBD) and
include intestinal epithelial cells; innate lymphoid cells;
cells of the innate immune system such as monocytes,
macrophages, neutrophils, and dendritic cells (DCs); the
adaptive immune system with T and B cells; and their se-
cretion products (chemokines, cytokines) (Fig. 1). Inves-
tigating the microbiome will come up with new theories
on the etiology of IBD. Thus, the increasing knowledge
of the interaction between the innate and adaptive im-
mune systems as well as the microbiome in the context
of the individual genetic background might be helpful
for personalized therapy in IBD in the future. Indeed,
the intestinal mucosa is host to a massive number of intes-
tinal macrophages resident in the mucosa which continu-
ously demonstrate phagocytic activity, and blood monocytes
are recruited to the lamina propria, normally quickly
undergo induction of anergy but interestingly retain many
proinflammatory activities in inflamed mucosa. Although
the exact cause of CD remains unknown, new pathogenic
paradigms in IBD have highlighted that the interactions
between various constituents of the innate and adaptive
immune systems play key roles in the pathogenesis of IBD
[2]. As the frontiers of immunological research expand,
new insights into the pathogenesis of IBD are opening up
new possible avenues for treatment. Myeloid-derived cells
including monocytes/macrophages long thought to be ef-
fector cells driving the initiation of inflammation have been
increasingly shown to have immunoregulatory effects previ-
ously under-appreciated. Recent work suggests an import-
ant protective role of monocytes/macrophages and possible
homeostatic mechanisms to restrain acute and chronic in-
testinal inflammation (reviewed in [3]). This brief review
highlights the important role of immunoregulatory mono-
cytes in IBD and the role of granulocyte macrophage
colony-stimulating factor (GM-CSF) in maintaining the
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intestinal immune homeostasis in CD. For earlier and
more detailed literature on the immunoregulatory role of
myeloid-derived cells in IBD, the reader is referred to
prior reviews ([3] and references cited therein).
Role of monocytes/macrophages and GM-CSF in
the immunology of mucosal diseases
Monocytes and their derivative cells play an important
role in the pathophysiology of IBD. Intestinal macro-
phages derived from blood monocytes play a key role in
sustaining the innate immune homeostasis in the intes-
tine [4]. Intestinal chronic inflammation may be caused
by inborn errors of macrophages in patients with CD.
Macrophages from CD patients are intrinsically defective,
with impaired secretion of cytokines that are normally
translated but internally degraded. Because of insuffi-
cient production of cytokines and chemokines, there is
impaired attraction of granulocytes to mucosal breaches.
Impaired acute, granulocytic inflammation results in im-
paired clearance of bacteria and debris from the gut wall,
itself resulting in chronic, granulomatous inflammation
[5, 6]. The cytokine GM-CSF promotes the differenti-
ation of monocytes into macrophages and DCs. There
is growing evidence that GM-CSF, or rather the lack
thereof, is implicated in the pathogenesis of CD. Hu-
man and murine studies showed that GM-CSF exerts
beneficial effects on intestinal inflammation. In addition, it
has been shown that increased levels of neutralizing
Fig. 1 Overview of the intestinal immune system. Innate immunity: Intestinal epithelial cells provide a physical barrier between the luminal microbes
and the underlying intestinal tissues to control defense and tolerance. Specialized epithelial cells produce a mucus layer (goblet cells) and secrete
antimicrobial proteins (Paneth cells) that limit bacterial exposure to the epithelial cells. Production of large amounts of immunoglobulin (Ig) A
provides additional protection from luminal microbiota. Innate microbial sensing by epithelial cells, dendritic cells, and macrophages is mediated
through pattern recognition receptors and induces various pathways that mediate microbial killing and activate adaptive immune cells. Adaptive
immunity: Dendritic cells present antigens to naïve CD4 positive (+) T cells in secondary lymphoid organs (mesenteric lymph nodes), where factors
such as the phenotype of the antigen-presenting cells and cytokine milieu modulate differentiation of proinflammatory T helper (Th) cell subsets (Th1,
Th17) with characteristic intestinal homing profiles and cytokines such as interleukin (IL)-17, IL-22, tumor necrosis factor alpha (TNFα), and interferon
gamma (IFNγ). Defense mechanisms that limit microbial entry into intestinal tissues also serve as a mechanism of tolerance. Activation of
unique populations of dendritic cells in the intestinal lamina propria does not result in secretion of proinflammatory cytokines. Those dendritic
cells present antigen to T cells in mesenteric lymph nodes, which leads to differentiation of regulatory (Treg) and anti-inflammatory (Th2) T cell
populations, mediated by transforming growth factor beta (TGFß), IL-4, IL-10, and IL-13
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endogenous serum GM-CSF autoantibodies (Ab) in CD
patients as well as decreased expression of the GM-CSF
receptor α-subunit (CD116) in circulating monocytes and
granulocytes of CD patients affect mucosal integrity, epi-
thelial barrier function, bacterial killing, and neutrophil
antimicrobial functions (reviewed in [7]).
GM-CSF also triggers several different signaling path-
ways in myeloid-derived suppressor cells (MDSCs) that
mainly involve the signal transducer and activator of tran-
scription (STAT) family of transcription factors. MDSCs
are a heterogeneous group of immature cells that includes
precursors of macrophages, granulocytes, DCs, and mye-
loid cells at earlier stages of differentiation. MDSCs ex-
pand rapidly during inflammation, infection, and cancer
and suppress T cell responses [8]. Although MDSCs have
been described in animal models of experimental colitis
and in patients with IBD, their exact role in IBD patho-
genesis is unclear [9]. As an additional homeostatic
function, GM-CSF has been proposed to be essential
for a microbiota-dependent crosstalk between mono-
nuclear phagocytes and group 3 innate lymphoid cells
(ILC3s) thereby promoting intestinal homeostasis. ILC3-
derived GM-CSF can promote intestinal myeloid cell
homeostasis through enhancing DC and regulatory T cell
function [10–13].
The potential for future cell-based therapies for IBD is
enhanced by the advances being made in the under-
standing of the innate immune system in the intestine.
Based on this, any therapeutic approach aimed at modu-
lating monocytes/macrophages as a key player in innate
immunity could be a potent way to modulate/manage
intestinal inflammation in patients with chronic intes-
tinal inflammation. However, the full action mechanism
of GM-CSF, and especially whether monocytes mediate
its therapeutic effects in vivo, had not been previously
elucidated.
Human GM-CSF-activated monocytes have
regulatory immune functions in vitro
We hypothesized that GM-CSF might activate monocytes
in a way that modulates their function during intestinal in-
flammation. We analyzed the immunoregulatory potential
of GM-CSF on human monocytes in vitro using micro-
array technology and functional assays taking all potential
functions of human GM-CSF-activated monocytes into
account (including gene expression, innate immune func-
tions, interplay with adaptive immunity, wound healing).
Our findings suggest that the early imprinting of mono-
cytes after activation with GM-CSF is of crucial import-
ance, because monocytes play an important role during
the recruitment phase of the innate immune response
and have the potential to regulate adaptive immune
mechanisms.
We showed that GM-CSF-activated monocytes combine
(i) an anti-inflammatory phenotype, (ii) features of aug-
mented innate immune functions (e.g., migration, chemo-
taxis, oxidative burst), (iii) the ability to facilitate epithelial
healing, and (iv) the regulatory potential on adaptive
immunity. GM-CSF-activated monocytes represent an
intermediate cell type, combining cell-surface expres-
sion characteristics and functional features of different
M2-type macrophage subsets [14]. In contrast with proin-
flammatory and antimicrobial responses of classically
activated M1-like monocytes, M2-like phenotypes are
broadly anti-inflammatory and play important roles in
wound healing [15]. In addition to these innate immune
functions, human GM-CSF-activated monocytes simul-
taneously have a regulatory potential on adaptive im-
munity. We showed that GM-CSF significantly induces
a short-termed expression of chemokines in monocytes,
which are known to attract naïve T cells, T helper 2
(Th2) cells, and/or regulatory T cells (Treg). Indeed,
migration of naïve, autologous T cells toward GM-CSF-
activated monocytes was accelerated in vitro. Our data
suggest that particularly CCL18 and CCL23 might be
responsible for the increased T cell migration. When
we cocultured GM-CSF-activated monocytes with syn-
geneic CD4+ T cells, we observed that GM-CSF-activated
monocytes attract T cells and shape their differentiation
toward Th2 cells by upregulating T cell-derived IL-4,
IL-10, and IL-13 and downregulating T cell-derived
IFNγ in vitro. In addition, cocultures of GM-CSF-
activated monocytes and naïve T cells led to an induc-
tion of Treg, which produce anti-inflammatory IL-10
and TGFβ and have important anti-inflammatory func-
tions [14].
Finally, we showed that GM-CSF may regulate the
homing molecules CCR2 and CCR6 on human mono-
cytes [14], which are involved in regulating several as-
pects of mucosal immunity, including the ability to
mediate the recruitment of innate immune cells to the
sites of epithelial inflammation.
Murine GM-CSF-activated monocytes as an anti-
inflammatory player in the intestine
After having analyzed the specific activation pattern of
human monocytes in response to GM-CSF in vitro, we
next aimed to address the functionality of these cells in
vivo in the context of CD. Because systematic analyses
in the human system are not feasible, we went on ana-
lyzing the effects of GM-CSF-activated monocytes on the
murine system. In the first step, we activated bone-
marrow-derived murine monocytes with GM-CSF in vitro
and analyzed the phenotype and functional properties of
murine GM-CSF-activated monocytes in vitro.
Our gene expression analyses showed that murine
GM-CSF-activated monocytes have a similar gene
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regulation profile when compared with the GM-CSF-
dependent gene expression in human monocytes [14].
Like human GM-CSF-activated monocytes, murine GM-
CSF-activated monocytes did not fit into current mono-
cyte subtype definitions dividing monocytes/macrophages
according to cell surface markers and functions in classic/
inflammatory (M1), intermediate, and alternative/anti-in-
flammatory (M2) cells. After activation with GM-CSF,
murine monocytes were found to overexpress some sur-
face markers of specialized macrophages and some stimu-
latory molecules while showing decreased expression of a
marker for alternatively activated monocytes. In addition,
we noted discrepancies in the expression levels of some
M2-polarized markers. Because this expression profile did
not fully recapitulate the previously reported activation
stages of monocytes, we proposed that the newly gener-
ated monocytes represented a unique and distinct state of
activation. These murine GM-CSF-activated monocytes
were also found to be somewhat unique from a functional
point of view. We demonstrated in vitro that this popula-
tion has a lower capacity for phagocytosis and adhesion
but triggers increased generation of reactive oxygen spe-
cies, which are required for pathogen clearance. Moreover,
after lipopolysaccharide treatment, proinflammatory cyto-
kine production was found to be higher in GM-CSF-
activated monocytes compared with untreated monocytes.
However, despite their phenotypical and functional diver-
sity, murine GM-CSF-activated monocytes mainly seem
to represent monocytes in a developmental stage passing
toward M2-polarized macrophages with an upregula-
tion of M2 markers and important anti-inflammatory
functions [16].
In addition, we performed flow cytometry-based stain-
ing of various gut homing molecules on monocytes and
found, in agreement with our studies on human GM-
CSF-activated monocytes, CCR2, necessary for migration
toward inflammatory sites, and CCR6, used for the mi-
gration toward lymph follicles such as Peyer patches,
to be upregulated on murine GM-CSF-activated mono-
cytes [16].
Murine GM-CSF-activated monocytes reduce se-
verity of experimental colitis
In the next step, we tested whether GM-CSF-activated
monocytes have a protective and therapeutic effect
against intestinal inflammation in vivo. Since none of
the currently available animal models of IBD reflects all
aspects of IBD in humans, we used various mouse
models of chronic colitis. Firstly, we showed that Rag1-
deficient mice (which lack all mature adaptive immune
cells) were protected from disease progression during
CD4+CD25− T cell-induced experimental colitis when
they received GM-CSF-activated monocytes but not un-
treated monocytes. In agreement with earlier work, we
found that Rag1-deficient mice that did not receive GM-
CSF-activated monocytes but GM-CSF intraperitoneally
after the transfer of T cells were not completely pro-
tected from colitis but showed reduced disease severity.
Our data demonstrate that the protective effect of
monocytes depends on their GM-CSF pre-activation in a
T cell-dependent model of colitis [14]. Secondly, we in-
duced chronic colitis in wild-type mice by repetitive ad-
ministration of dextran sulfate sodium (DSS) in drinking
water. Mice treated with GM-CSF-activated monocytes
were again completely protected from experimental col-
itis [16]. Thirdly, we induced chronic colitis in Rag1-
deficient mice with DSS. Injection of GM-CSF-activated
monocytes was not able to protect Rag1-deficient mice
against DSS-induced colitis, indicating that adaptive im-
munity is required for the protection mediated by GM-
CSF-activated monocytes [16].
We next sought to decipher the mechanism by which
GM-CSF-activated monocytes confer their therapeutic
effects on intestinal inflammation. We found that, com-
pared with control monocytes, the GM-CSF-activated
monocytes were taken up faster by the inflamed intes-
tine and stayed there longer, especially in Peyer patches
[14, 16]. In addition to these unique migratory features
and in agreement with our in vitro findings, accelerated
gut homing of GM-CSF-activated monocytes was accom-
panied by increased production of the anti-inflammatory
Th2 cytokines IL-4, IL-10, and IL-13 and decreased pro-
duction of the proinflammatory Th1 cytokine IFNγ in in-
testinal lamina propria mononuclear cells and mesenteric
lymph nodes in vivo during colitis [14]. Furthermore,
GM-CSF-activated monocytes increased the accumulation
of Foxp3+ Tregs in the lymph follicles of mice with ex-
perimental colitis when compared with untreated mice
or those treated with nonactivated monocytes. In an in
vitro model in which GM-CSF-activated monocytes
were cocultured with naïve T cells, we observed in-
creased proliferation and differentiation of Foxp3+ Treg
cells and found that this occurred through a mechan-
ism that involves the CD39-mediated conversion of
ATP into adenosine—a mechanism that was previously
reported to induce Treg cell differentiation [16].
Taken together, these important data show that GM-
CSF-activated monocytes are a specific population of
monocytes that has a protective effect against intestinal
inflammation (Fig. 2). The beneficial effects of GM-CSF-
activated monocytes are T cell dependent and involve
the CD39/adenosine-mediated proliferation and differ-
entiation of Foxp3+ Treg cells. This is in agreement with
the work of others, who showed that GM-CSF can influ-
ence the interactions between DCs and T cells and in this
manner determine a pro- versus anti-inflammatory adap-
tive immune response via Th1 and Th17 cell responses or
the induction of Treg cells, respectively [17–20].
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Neutralization of GM-CSF is associated with dis-
ease relapse in CD patients
GM-CSF bioactivity varies inversely with increasing
serum levels of endogenous neutralizing GM-CSF auto-
antibodies (Ab). GM-CSF Ab as well as defective GM-
CSF receptor expression have been described in IBD
[21–25]. Increased GM-CSF Ab levels are associated
with alterations of epithelial barrier function, bowel per-
meability, bacterial translocation, neutrophil antimicro-
bial functions, and epithelial cell survival and proliferation
[7, 21–24, 26, 27]. A rare familial form of pulmonary al-
veolar proteinoses may also serve as an established model
to highlight the role of Ab toward GM-CSF resulting in
blocking GM-CSF-driven responses [28, 29]. This sug-
gested that variation in GM-CSF Ab and thereby GM-
CSF bioactivity might also be associated with clinical
disease relapses in patients with CD. In order to valid-
ate these findings, we determined GM-CSF Ab levels in
prospectively collected serum samples of pediatric and
adult patients with CD. Time course analysis of GM-
CSF Ab up to 9 months before and after relapse showed
a clear increase of Ab titers up to 6 months before clin-
ical relapse followed by a steady decrease, likely indicat-
ing the success of the intensified therapies. In addition,
we found that GM-CSF Ab levels in serum samples of
patients with IBD who had no clinical disease relapse
during the study follow-up showed a low intra-individual
variation and GM-CSF Ab levels were below the cut-point
where GM-CSF Ab start to inhibit neutrophil antibacterial
function [30]. Thus, an elevated serum GM-CSF Ab titer
in patients with CD in clinical remission as defined by
clinical disease activity scores may represent an early stage
of increased intestinal permeability, bacterial transloca-
tion, neutrophil dysfunction, and reduced antimicrobial
activity (reviewed in [31]). It is conceivable that the po-
tentially impaired intestinal homeostasis progresses to
Fig. 2 Mechanisms of immunoregulation by GMaM in inflammatory bowel disease. The early imprinting of monocytes following activation with
GM-CSF is of crucial importance, since monocytes play an important role during the early (recruitment) phase of the innate immune response in
the intestine. GMaM represent a unique and distinct state of activation combining phenotypical and functional features of different M2 macrophage
subsets. GMaM trigger augmented host defense functions including an increased generation of reactive oxygen species, which are required
for pathogen clearance. GMaM have a higher capacity for adherence, migration, and chemotaxis; they attract T cells and have the potential to
regulate adaptive immune mechanisms by induction of anti-inflammatory T helper 2 cells (Th2) and regulatory T cells (Treg). Furthermore,
GMaM have the ability to facilitate epithelial/mucosal healing and to ameliorate intestinal inflammation. GMaM granulocyte macrophage
colony-stimulating factor (GM-CSF)-activated monocytes
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cause an eventual clinical relapse of the disease and un-
derpins the beneficial role of GM-CSF in the context of
intestinal homeostasis.
Blood monocytes from patients with CD behave
like GM-CSF-activated monocytes
Our phenotypic and functional studies showed that per-
ipheral blood monocytes from CD patients in clinical re-
mission are not impaired compared to healthy controls
[32]. We next studied phenotypic and functional features
of untreated versus GM-CSF-activated peripheral blood
monocytes of patients with quiescent CD. Collectively,
our data suggest that the effects of GM-CSF activation
of peripheral blood monocytes from patients with CD
are similar to the observed effects of GM-CSF-activated
monocytes from healthy donors. This included the
GM-CSF-induced increase in adherence, migration,
chemotaxis, and oxidative burst, as well as the priming of
monocytes to secondary microbial stimuli. In addition,
changes in GM-CSF-dependent mRNA expression of se-
lected key inflammatory cytokines were in agreement
with our transcriptomic data obtained from GM-CSF-
activated monocytes of healthy individuals. Importantly,
there was no evidence that GM-CSF activation had dif-
ferent effects on monocytes when compared between
individual CD patients [14].
Myeloid-specific STAT3 activation ameliorates
experimental colitis via MDSCs
Several studies have investigated the mechanisms of
MDSC T cell suppressive activity in health and disease
including experimental colitis models and human IBD
[8, 9]. MDSC expansion is regulated by several factors
(including GM-CSF) that are released during inflamma-
tion, infection, and cancer. The signaling pathways in
MDSCs converge on Janus kinase (JAK) protein family
members and STAT3. Hyperactivation of STAT3 in
gp130757F/F mice is associated with protection from
DSS-induced colitis. We hypothesized that the protect-
ive role of gp130-dependent STAT3 activation in experi-
mental IBD involves the expansion and activation of
MDSCs, in addition to the previously reported prolifera-
tive, regenerative, and survival effects on intestinal epi-
thelial cells. We therefore induced acute and also
chronic colitis with DSS and analyzed the effects in mice
with systemic hyperactivation of STAT3 (gp130757F/F) ±
myeloid-specific STAT3-deficiency (LysMcre/STAT3flox).
We showed that the resistance to DSS-induced acute
colitis in gp130757F/F mice is via myeloid cell-specific
STAT3 activation, expansion of granulocytic MDSCs in
the colon, and increased production of suppressive and
protective mediators. Interestingly, gp130757F/F mice were
not resistant to chronic DSS-induced colitis [33].
Thus, our study identified new immunoregulatory
mechanisms of STAT3 during intestinal inflammation.
Importantly, the adoptive transfer of MDSCs in different
animal models of IBD ameliorates colitis and suggests
that MDSCs may be used as the basis for a novel adop-
tive cellular cell therapy in IBD ([3] and references cited
therein). However, MDSCs may either promote or sup-
press T cell functions depending on the stage of disease
and/or other external factors. Indeed, there is also evi-
dence supporting a proinflammatory role of myeloid
cells in experimental IBD [34–36]. In addition, an in-
crease in the frequency of MDSCs in the peripheral
blood from patients with active chronic colitis has been
reported [37].
Summary and future perspectives
The work of others and our in vitro and in vivo data
show that GM-CSF-activated monocytes are a specific
population of monocytes that has a protective effect
against intestinal inflammation as shown in various inde-
pendent mouse models of experimental colitis. The
beneficial effects of GM-CSF-activated monocytes are T
cell dependent and involve the proliferation and differ-
entiation of Th2 and Treg cells in the intestine (Fig. 2).
Thus, our in vitro and in vivo findings support the ex-
ploration of stimulating rather than suppressive therap-
ies with the potential to more specifically reprogram
monocytes toward immunoregulatory functions to allevi-
ate chronic CD. Even though previous clinical trials
showed that systemic administration of GM-CSF might
have therapeutic effects in a subgroup of patients with
CD (reviewed in [38]), it is important to consider that
key aspects of GM-CSF biology and unwanted side ef-
fects of systemic administration still need to be clarified
[39]. Adverse events commonly associated with systemic
GM-CSF administration include injection site reactions,
bone and musculoskeletal chest pain, pulmonary capil-
lary leak syndrome, pulmonary edema, heart failure,
fever, and neurotoxicity. In addition, in many pre-clinical
models of inflammation and autoimmunity, GM-CSF
neutralization or deletion suppresses a number of dis-
eases including the following: arthritis, experimental
autoimmune encephalomyelitis, lung inflammation and
disease (asthma and chronic obstructive pulmonary dis-
ease), nephritis, psoriasis, atherosclerosis, cancer (e.g.,
breast cancer), Alzheimer’s disease, myocardial infarc-
tion, peripheral insulin resistance, and inflammatory pain.
Thus, beneficial effects of GM-CSF-driven tolerance in
CD seem somewhat counterintuitive, as GM-CSF is gen-
erally regarded as a cytokine with more proinflammatory
functions based on its activity on neutrophils and macro-
phages. It is likely that GM-CSF plays both protective and
pathological roles in IBD and that the context in which it
is produced might determine its ultimate functional role.
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Recent work, for example, showed that GM-CSF pro-
motes IL-23-driven intestinal inflammation through local
accumulation of activated eosinophils and potentiation of
their effector functions [40]. A targeted cell-based ap-
proach using GM-CSF-activated monocytes represents a
safer and more promising treatment option given the
pleiotropic and proinflammatory effects of GM-CSF on
inflammation and autoimmunity (reviewed in [41]). Given
the contrasting roles for GM-CSF in immunopathology,
our work helps to strengthen the link between GM-CSF
and IBD [42] and is opening up new possible avenues for
a personalized IBD treatment.
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